| __timestamp | PTC Therapeutics, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44820000 | 10811000 |
| Thursday, January 1, 2015 | 82080000 | 33001000 |
| Friday, January 1, 2016 | 97130000 | 64936000 |
| Sunday, January 1, 2017 | 121271000 | 99909000 |
| Monday, January 1, 2018 | 153548000 | 127724000 |
| Tuesday, January 1, 2019 | 202541000 | 161524000 |
| Wednesday, January 1, 2020 | 245164000 | 182933000 |
| Friday, January 1, 2021 | 285773000 | 219982000 |
| Saturday, January 1, 2022 | 325998000 | 278139000 |
| Sunday, January 1, 2023 | 332540000 | 309799000 |
Unleashing insights
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining financial health. From 2014 to 2023, PTC Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. have shown distinct trends in their SG&A expenditures. PTC Therapeutics has seen a consistent rise, with expenses growing by approximately 640% over the decade. In contrast, Ultragenyx's SG&A costs increased by about 280% during the same period. By 2023, PTC Therapeutics' SG&A expenses were about 7% higher than Ultragenyx's, indicating a more aggressive spending strategy. This data suggests that while both companies are expanding, PTC Therapeutics is investing more heavily in its administrative and sales functions. Investors and stakeholders should consider these trends when evaluating the companies' operational efficiencies and long-term strategies.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Ultragenyx Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.
Alkermes plc or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
PTC Therapeutics, Inc. vs Merus N.V.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.